US Patent

US7803770 — Method of treating osteoporosis comprising administration of PTHrP analog

Method of Use · Assigned to Ipsen Pharma SAS · Expires 2031-04-28 · 5y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) for treating osteoporosis.

USPTO Abstract

The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) and methods of using a PTHrP and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general may be stored at room temperature for at least several weeks to allow convenient parenteral administration to human patients.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2009 — Tymlos

Patent Metadata

Patent number
US7803770
Jurisdiction
US
Classification
Method of Use
Expires
2031-04-28
Drug substance claim
No
Drug product claim
No
Assignee
Ipsen Pharma SAS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.